Sandoz Achieves Primary Endpoint in Phase III Trial for Biosimilar Aflibercept
Switzerland-based Novartis (NYSE: NVS) subsidiary Sandoz (SWX: SDZ) has announced that a Phase III confirmatory...
Ophthalmology
Lee’s Pharmaceutical’s Subsidiary Completes Phase III Study for Myopia Treatment NVK002
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary, Zhaoke Ophthalmology Ltd (HKG: 6622), has announced...
Eyebright Medical Technology’s Intraocular Lenses Earn Fast-Track Status in China
Beijing-based Eyebright Medical Technology Co., Ltd (SHE: 688050) has announced that its “intraocular lenses with...
CORXEL Gets CDE Approval for Phase III Presbyopia Trials of LNZ100 and LNZ101
Shanghai-based CORXEL, formerly known as Ji Xing Pharmaceuticals, supported by RTW Investments, has announced that...
Lee’s Pharmaceutical Subsidiary Zhaoke Ophthalmology Partners with Eyebright Medical Technology
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary, Zhaoke Ophthalmology Ltd (HKG: 6622), has entered...
Shanghai Henlius Completes Phase I/II Study for Anti-VEGF mAb HLX04-O in Wet AMD
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) subsidiary, Shanghai Henlius Biotech, Inc....
Ocumension Therapeutics’ OT-101-S Myopia Treatment Accepted for CDE Review
Chinese ophthalmology specialist Ocumension Therapeutics (HKG: 1477) has announced that the Center for Drug Evaluation...
Beyond Therapeutics Secures Tens of Millions in Pre-Series A Financing for Ophthalmology and Oncology Pipeline
Beyond Therapeutics Co., Ltd., a biotechnology company based in Suzhou with a focus on ophthalmology...
Ji Xing Pharmaceuticals and TSH Biopharm Announce Collaboration for Dry Eye Treatment in Taiwan
Shanghai-based Ji Xing Pharmaceuticals, a company backed by RTW Investments, has announced a strategic collaboration...
Shanghai BDgene Technology Receives US FDA Approval for HSV-1 Stromal Keratitis Gene Therapy
Gene therapy specialist Shanghai BDgene Technology Co., Ltd has announced receiving approval from the US...
C-Mer Eye Care Holdings Ltd Partners with Hong Kong Ophthalmologist for Novel Drug Development
China-based C-Mer Eye Care Holdings Ltd (HKG: 3309) has announced the establishment of a joint...
Australian Scleral Lens Epicon A Approved by China’s NMPA as 10th Novel Product
Ruitai Bio’s Epicon A, a scleral lens product from Australia, has been approved by the...
Genevector Initiates Clinical Study for JWK001 in Neovascular Age-Related Macular Degeneration
Chengdu-based adeno-associated virus (AAV) gene therapy developer, Genevector Biotechnology Co., Ltd., has announced the first...
Lee’s Pharmaceutical Secures Rights to Eyedetec’s Dry Eye Device in Asia-Pacific
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) through its subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622)...
Lee’s Pharmaceutical Subsidiary Zhaoke Ophthalmology Announces FDA Review of NVK002 for Pediatric Myopia
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary, Zhaoke Ophthalmology Ltd (HKG: 6622), has announced...
Neurophth Biotechnology Partners with Sinopharm Group to Commercialize Gene Therapy NFS-01
China-based gene therapy specialist Neurophth Biotechnology Ltd has announced a strategic partnership with compatriot firm...
Oculis’ OCS-01 Achieves Primary Efficacy Endpoint in Phase III DIAMOND Trial for DME
US-based Oculis Holding AG (NASDAQ: OCS) has announced positive top-line results from Stage 1 of...
CDE Lists Three Home-Grown Drugs for Priority Review, Including Myopia Treatment
The Center for Drug Evaluation (CDE) website has indicated that three home-grown drugs are on...
Skyline Therapeutics Initiates Clinical Study with First Patient Dosing of SKG0106 for wAMD
Skyline Therapeutics has reached a significant milestone with the completion of the first patient dosing...
Betta Pharmaceuticals and EyePoint Pharmaceuticals Submit EYP-1901 for NMPA Review
China’s Betta Pharmaceuticals (SHE: 300558) has announced that the clinical trial filing for its EYP-1901...